SCHEMBL5453432

SCHEMBL5453432

O=C(O)c1c(NC(=O)C2CC2)sc2c1CCOC2

nearest known ligand 0.71

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 3/20 0.71
PTPRC P08575 1/20 0.71
PTPN2 P17706 1/20 0.71
PTPRB P23467 1/20 0.71
PTPRE P23469 1/20 0.71
CNR2 P34972 7/20 0.59
RAB7A P51149 2/20 0.57
FLT3 P36888 1/20 0.53
KDM4E B2RXH2 1/20 0.51
MAPT P10636 1/20 0.51
HSD17B10 Q99714 1/20 0.51
CFTR P13569 1/20 0.47
CNR1 P21554 2/20 0.47
KMT2A Q03164 2/20 0.46
NOD1 Q9Y239 1/20 0.46
ANO1 Q5XXA6 3/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3760411 0.94 PTPN1 (0.67) PTPN1PTPRCPTPN2PTPRBPTPRE
SCHEMBL5444948 0.88 FLT3 (0.70) PTPN1PTPRCPTPN2PTPRBPTPRE
SCHEMBL4090461 0.84 CNR2 (0.70) PTPN1PTPRCPTPN2PTPRBPTPRE
SCHEMBL5741314 0.83 PTPN1 (0.75) PTPN1PTPRCPTPN2PTPRBPTPRE
SCHEMBL4312414 0.83 PTPN1 (1.00) PTPN1PTPRCPTPN2PTPRBPTPRE
SCHEMBL5450973 0.83 FLT3 (0.67) PTPN1PTPRCPTPN2PTPRBPTPRE
SCHEMBL5459005 0.83 FLT3 (0.67) PTPN1PTPRCPTPN2PTPRBPTPRE
SCHEMBL29601491 0.83 PTPRC (0.70) PTPN1PTPRCPTPN2PTPRBPTPRE
SCHEMBL5449114 0.82 FLT3 (0.65) PTPN1PTPRCPTPN2PTPRBPTPRE
SCHEMBL5450569 0.82 KMT2A (0.69) CNR2KDM4EMAPTHSD17B10CNR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US claimed
EP-1670804-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC Biotech AG (DE) 2006-06-21 EP claimed
WO-2005023818-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC BIOTECH AG (DE) 2005-03-17 WO claimed
EP-1670804-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC Biotech AG (DE) 2006-06-21 EP disclosed
WO-2005023818-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC BIOTECH AG (DE) 2005-03-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents TBCA, PARK7, NFATC1 PTPN1 2192/4885PTPRC 1457/4885PTPN2 2364/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.